A Recombinant Acetylcholine Receptor α1 Subunit Extracellular Domain Is a Promising New Drug Candidate for Treatment Of Myasthenia Gravis

Overview of attention for article published in Frontiers in immunology, June 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 1 news outlet

twitter: 3 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 9 Mendeley

Summary News X Dimensions citations

So far, Dimensions has found 1 citation of this research output.

1

The most recent citing publication is shown below. View this citation on Dimensions.

Myasthenia gravis and independent risk factors for recurrent infection: a retrospective cohort study

Article in BMC Neurology (July 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.